The objective of the study was to analyse the treatment of high blood pressure (BP) and hypercholesterolaemia, as well as the effect of individual or combined antihypertensive-hypocholesterolaemic therapy on BP control and on circulating cholesterol. A retrospective study was performed using clinical data recorded in the general practitioner's database. The sample included all patients, aged 4/ ¼ 18 years, with BP reading or lowdensity lipoprotein (LDL) cholesterol measurement recorded between January 2003 and December 2004. BP and LDL cholesterol targets were defined using cutoffs based on the guidelines of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC7) and the National Cholesterol Education Program (NCEP/ATPIII). The study included 4764 patients (mean age 67.6711.8 years, 43.5% males). Target BP was achieved in a higher number of patients under combined antihypertensive-hypocholesterolaemic therapy than in those treated only with antihypertensives: 57.0 vs 50.0% in patients with history of cardio/cerebrovascular (CV) hospitalization, 27.0 vs 16.9% in patients with diabetes or chronic renal insufficiency (CRI) and 59.7 vs 49.1% in patients with no CV hospitalization nor diabetes and nor CRI. The LDL cholesterol target was achieved in 61.3% of the subjects: it was independent on the therapy (individual or combined), but related to the degree of cardiovascular risk. Analysing the data contained in the general medicine database made it possible to evaluate the treatment of high BP and hypercholesterolaemia in relation to cardiovascular risk
Introduction
Blood pressure (BP) regulation is the result of multiple interacting environmental and genetic factors, which act through pathophysiological mechanisms. 1, 2 The prevalence of hypertension increases with age, although high BP in the elderly may be regulated by different factors from those active in younger people. Effective BP control is a powerful tool for the reduction of cardiovascular events, regardless of the drugs used. [3] [4] [5] Several surveys over the past decades have shown that control of BP is far from adequate -systolic BP o140 mm Hg and diastolic BP o90 mmHg -in the large majority of hypertensive patients. 3, 6, 7 The same is true with regard to patients suffering from hypercholesterolaemia [8] [9] [10] [11] in whom the use of statins is definitely inconsistent with the ATPIII recommendations. 12 Thus, the application of guidelines on the management of hypertension and hypercholesterolaemia is certainly unsatisfactory.
Vascular reactivity may be influenced by circulating cholesterol both in experimental hypertension and in humans. [13] [14] [15] [16] A positive correlation between BP and cholesterol levels has been suggested. 16, 17 In a double-blind, placebo-controlled study, effective control of circulating low-density lipoproteins (LDL) cholesterol by pravastatin significantly reduced BP in previously untreated mild-to-moderate essential hypertensive patients. 18 The clinical trials on the analysis of the effect of statins on BP showed contrasting results. 19, 20 Although promising, these data still remain confined to the quite 'artificial world' of the controlled clinical studies whereas their importance, if any, in the 'real world' of the daily clinical practice is still to be defined. In the 'real-world' setting, the concurrent treatment of co-morbidities, either occasional or chronic, is likely to interfere with the efficacy of antihypertensive treatment or patient's compliance. 21, 22 One of the strengths of the Pandora project is the possibility of making several kinds of scientific analyses based on a large, prospective, collaborative database created over the past decade by the general practitioners (GPs) of the Ravenna province, northern Italy. 23 The aim of the present study was to provide a 'real-world instant picture', based on the Pandora database, of the treatment of high BP and hypercholesterolaemia, as well as the effect of individual or combined antihypertensive-hypocholesterolaemic therapy on BP control and on circulating LDL cholesterol.
Materials and methods

Data collection and patients
Fifty of 330 GPs in the Ravenna area, Italy, voluntarily participated in the Pandora project. In Italy, the GP is the doctor working outside the hospital who is delegated by the National Health System to provide care for a known number of subjects. The GPs participating in the project had a total cohort of about 55 000 beneficiary subjects who represent 15.7% of people living in the Ravenna area. The Pandora project was approved by the Local Ethics Committee and each patient enrolled gave informed consent. All GPs were supplied with a personal computer that was connected to a remote server via modem, a printer, an automatic BP device (Dinamap 1846SX, Critikon, Tampa, FL, USA) and a dedicated software package called So.Ge.Pa. Clinical and laboratory data were gathered and stored either by the GPs themselves or through links with Health Service databases, as already documented. 23 The antihypertensive drugs and lipid-lowering drugs (LLDs) prescribed to each patient were identified from the GP database, which logs each prescription, records the code number of the prescribing physician, the national health number of the patient, the date dispensed, the AnatomicalTherapeutic-Chemical classification (ATC -the ATC system is used for the classification of drugs; the classification categorizes substances at five different levels according to the organ or system on which they act and/or their therapeutic, pharmacologiacal and chemical characteristics), the number of packs and the number of tablets per pack. Records of any hospitalizations, identified by the ICD 9 CM (International Classification of Diseases, ninth revision) code, were derived from the hospital database kept by the Local Health Unit of Ravenna.
Study design, patient characteristics and measurement of outcomes
The data examined included all the patients X18 years old with at least one BP reading or one LDL cholesterol measurement during the enrollment period, defined as from 1 January 2003 to 31 December 2004. The analysis considered the most recent BP readings and cholesterol levels. The follow-up period was defined retrospectively and consisted of the 12 months before the first BP or cholesterol measurement. The antihypertensive treatment was analysed in the patients cohort with at least one BP measurement, the lipid-lowering treatment in the cohort of patients with at least one LDL cholesterol measurement. The combined antihypertensive and lipid-lowering treatment was analysed in the cohort of patients with BP and a LDL cholesterol measurements.
The patients who were treated exclusively with diuretics (code ATC C03), b-blockers (code ATC C07), calcium antagonists (code ATC C08), angiotensin-converting enzyme (ACE) inhibitors (code ATC C09A), angiotensin II antagonists (code ATC C09C) or other antihypertensive drugs (code ATC C02) during the retrospective follow-up period were considered as treated with antihypertensive drugs alone. Patients only prescribed statins (ATC code C10AA), fibrates (ATC code C10AB), bile acid sequestrants (ATC code C10AC), nicotinic acid and derivates (ATC code C10AD) or other hypocholesterolaemic and hypotrygliceridaemic drugs (ATC code C10AX) during the follow-up period were considered as treated only with LLDs. The patients receiving a combined treatment of antihypertensives and LLDs during the follow-up period were considered as treated with antihypertensives and LLDs.
In patients treated with antihypertensive drugs, BP control was assessed by considering different BP thresholds in relation to the following patient characteristics: previous hospitalization for cardio/ cerebrovascular (CV) events (o140/90 mmHg), diabetes or chronic renal insufficiency (CRI) (o130/ 80 mmHg), none of the previous (o140/90 mmHg). 3 In the patients treated with LLDs, the control of cholesterol levels was assessed by considering different LDL cholesterol levels, in relation to the following classes of cardiovascular risk:
12 presence of ischaemic heart disease or diabetes (o100 mg/dl), presence of hypercholesterolaemia as well as two or more other cardiovascular risk factors (males aged 45 years or more and females aged 55 years or more; family history of premature ischaemic heart disease; smoking; hypertension -systolic BP X140 mmHg or diastolic BP X90 mmHg or antihypertensive treatment; high-density lipoprotein (HDL) cholesterol o40 mg/dl) (o130 mg/dl), presence of one cardio-vascular risk factor or just hypercholesterolaemia (o160 mg/dl).
Treatment features
Use of antihypertensive and lipid-lowering agents was defined, for the purpose of this study, as the mean daily dose (MDD) of the drugs prescribed during the retrospective follow-up period expressed as the number of tablets per day. The MDDs were obtained by using the following formula: number of tablets prescribed from the first to the penultimate prescription, divided by the number of days from the first to the last prescription. To measure the adherence to the treatment, the MDDs obtained in this way were standardized according to the defined daily doses (DDDs), as already documented. 24, 25 The patients who presented a standardized MDD greater than 0.80 were defined as adherent to treatment.
Statistical analysis
Continuous variables are presented as mean values7s.d. The statistical significance between means was calculated by one-way analysis of variance. The association between categorical variables was tested using the Pearson's w 2 test. The effect of the combined treatment (antihypertensives þ LLDs) on the control of BP was analysed with a multivariate logistic regression model, 26 which allowed to check the potential influences of the following variables: patient age, gender, presence/absence of associations between different classes of antihypertensive drugs, the MDD of antihypertensive drugs, presence/absence of previous CV hospitalizations, presence/absence of antidiabetic drugs, presence/absence of platelet inhibitors, presence/absence of CRI, presence/absence of family history of premature ischaemic heart disease, smoking and presence/absence of low levels of HDL cholesterol (o40 mg/dl).
The logistic regression model was also used to assess whether the patients on combined treatment (antihypertensive þ LLDs) presented a higher proportion of cardiovascular risk factors, even after eliminating the age effect. Table 1 ). The subjects on combined treatment (antihypertensive þ LLDs) were older (Po0.001), presented a higher proportion of patients with previous CV hospitalization (Po0.001), a higher proportion of diabetics (Po0.001), a higher proportion of patients treated with platelet inhibitors (Po0.001). Even after eliminating the age effect, the subjects receiving combined treatment presented significantly higher proportions (Po0.001) of these risk factors. There were 33.7% of patients taking antihypertensives who were treated with ACE inhibitors, 13.7% with calcium antagonists, 10.2% with b-blockers, 10.1% with angiotensin II antagonists, 6.8% with diuretics, 2.2% with other antihypertensives and 23.3% with an antihypertensive combination therapy. Among the patients taking LLDs, 86.3% were being treated with statins, 5.9% with other hypocholesterolaemic and hypotriglyceridaemic drugs, 5.5% with fibrates, 0.7% with bile acid sequestrants and 1.6% with a lipidlowering combination therapy.
The control of BP was assessed separately in the cohort of patients with a history of CV episodes, in the cohort of patients without CV hospitalization who presented diabetes or CRI, in the cohort of patients without CV hospitalization or diabetes, nor renal insufficiency. The number of patients in these cohorts is shown in Table 2 . In the patients with a history of CV hospitalization, the target BP (TBP) (Table 3) . When covariates were included in the analysis to adjust for potential confounders, the probability of failing to control the BP values was significantly lower (Po0.001) in the patients treated with a combination of antihypertensive and LLDs as compared with those treated exclusively with antihypertensive drugs. The adjusted relative risk reduction was 27% (confidence interval 95%: 13-38%). The adjusted positive effect of the combined treatment on BP control remained the same, even when subjects treated with non-statin drugs were excluded.
The control of LDL cholesterol was assessed separately in the cohort of patients with ischaemic heart disease or diabetes, in the cohort of patients with two or more cardiovascular risk factors, in the cohort of patients with one cardiovascular risk factor or just hypercholesterolaemia. The number of patients in these cohorts is shown in Table 4 . Among the patients with ischaemic heart disease or diabetes, the target LDL cholesterol (o100 mg/dl) was reached by 46.7% of the patients treated with LLDs alone and by 40.2% of those receiving a combined treatment (antihypertensive and LLDs). Among the patients with two or more cardiovascular risk factors, the target LDL cholesterol (o130 mg/dl) was reached by 56.0% of the patients treated with LLDs alone and by 67.6% of those receiving a combined treatment. Among the patients with a low cardiovascular risk, the target LDL cholesterol (o160 mg/dl) was reached by 80.7% of the patients treated with LLDs alone and by 75.0% of those receiving a combined treatment (Table 5 ). In general, about 51% of hypertensive patients and 39% of hypercholesterolaemic patients did not reach the target set by guidelines.
The analyses on the MDDs have shown that the proportions of subjects adherent to antihypertensive treatment were 84.4% in the cohort of patients with a history of CV episodes, 82.1% in the cohort of patients without CV hospitalization who presented diabetes or CRI, 73.8% in the cohort of patients without CV hospitalization or diabetes, nor renal The following risk factors were considered: males aged 45 years or more and females aged 55 years or more; family history of ischaemic heart disease; smoking; hypertension (systolic BP X140 mm Hg or diastolic BP X90 mm Hg, or presence of antihypertensive treatment); HDL cholesterol o40 mg/dl.
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insufficiency (Po0.001). The proportions of subjects adherent to lipid-lowering treatment were 74.4% in the cohort of patients with ischaemic heart disease or diabetes, 66.0% in the cohort of patients with two or more cardiovascular risk factors, 59.8% in the cohort of patients with one cardiovascular risk factor or just hypercholesterolaemia (Po0.001).
Discussion
The present study was intended as an instant picture in the setting of the usual daily clinical practice. A prospectively collected database -the Pandora database -was used for the present analysis. The Pandora database is the product of a prospective, collaborative data collection protocol in the cardiovascular field originated from the predefined collaboration between GPs of the province of Ravenna, Italy, and a second level specialized clinical centre. 23 The protocol was designed with the aim to generate local guidelines mirroring the reality, to permit a correct allocation of financial resources. The methodology of data collection and analysis used in the present study, although unusual, is on the other hand functional to the aims, to obtain an unequivocal instant picture of what happens in the real daily clinical practice with regard to treatment of high BP and hypercholesterolaemia in relation to cardiovascular risk.
In our study, about 49.0 and 61.3% of the subjects had their BP and LDL cholesterol, respectively, on target. Although still unsatisfactory, these numbers are definitely higher than those reported in the literature. 3, [6] [7] [8] [9] [10] [11] In particular, 50% of the patients treated with antihypertensives alone, with previous CV hospitalization (secondary prevention) showed a good control of BP (systolic BP o140 mmHg and diastolic BP o90 mmHg); a similar percentage of patients without diabetes mellitus, chronic kidney failure or previous CV hospitalization (primary prevention) reached the same BP target. On the contrary, only 16.9% of the patients presenting diabetes mellitus or chronic kidney failure had controlled BP (systolic BP o130 mmHg and diastolic BP o80 mmHg). The same trend was evident, but with higher percentages, for subjects treated with antihypertensives and LLDs. This different BP response may be due in part to the lower BP target (130/80 vs 140/90 mmHg), which is comprehensibly harder to achieve; nevertheless, even when the same BP target was considered (o140/90 mmHg), the percentage of diabetic and CRI patients showing BP control was lower compared with the other categories of subjects, suggesting a certain degree of 'resistance' to antihypertensive therapy in this group of patients.
Moreover, we reported on the LDL cholesterol response to treatment in our cohort: in subjects with LLDs alone, we observed a satisfactory LDL cholesterol control in individuals with one or no additional CV risk factors (80.7%) and progressively lower control in those with X2 additional risk factors or in secondary prevention (56.0 and 46.7%, respectively). Again, a similar trend was evident for subjects treated with the combined therapy (75.0 vs 67.6 vs 40.2%). These values certainly mirror the progressive difficulty of achieving the target as this becomes more stringent. In fact, when the same LDL cholesterol target is considered, a higher percentage of success is shown by patients with ischaemic heart disease or with diabetes irrespective of their treatment compared with the other subjects categories: this may suggest that the perception of a high global risk of a vascular event by both the patient and the GP drives an aggressive approach towards achieving lipid goals. This conclusion is confirmed by the finding that adherence to treatment is higher in patients with previous cardiovascular events.
The second point of our aim was to analyse the effect of individual or combined antihypertensive- hypocholesterolaemic therapy on BP control and on LDL cholesterol. In subjects with combined therapy, the probability of achieving the BP target was higher than in subjects with antihypertensives alone, whatever category of CV risk was considered and after adjusting for the influencing effect of other covariates. On the contrary, the combination of antihypertensives with LLDs was not associated with a consistent increase in the control of LDL cholesterol for all the cardiovascular risk classes. Some considerations can be made concerning the limits of this study. In the first place, the results come from a single geographic area in Italy. The findings, however, are in line with the results of other studies carried out in other parts of Italy 27, 28 and contribute to a more detailed picture of the Italian situation. In the second place, our pharmaceutical database does not contain information on the prescribed daily doses; therefore, compliance with drug treatment was estimated on the basis of the DDDs which is, nonetheless, a useful instrument for comparing the results from different pharmacoeconomic studies. 24 Finally, although we attempted to control for differences in baseline characteristics between combined therapy and monotherapy groups using a multivariate regression model, this technique cannot eliminate bias related to unmeasured or unknown covariates. However, the availability in our database of several potential confounders (including both anagraphic and clinical data) should have guaranteed an exhaustive control of confounding, 26 allowing to assess the independent effect of the combined treatment on the control of BP.
On the other hand, a strong point of our study is the joint use of the administrative archives, kept by the Local Health Unit and the general medicine archives. This integration made it possible to analyse, in the context of real clinical practice, numerous aspects concerning the management of hypertension and hypercholesterolaemia, such as the effect of individual or combined antihypertensive-hypocholesterolaemic therapy on BP control and on circulating cholesterol, the prevalence of cardiovascular risk factors in relation to the different type of treatment, the control of LDL cholesterol and BP values in cohorts of patients with different cardiovascular risk profiles. Our data are even more relevant as they were obtained in patients likely to be affected by the interference of other therapies such as anti-inflammatory drugs which may attenuate the effects of antihypertensives. On the other hand, we could not control for the possible effect of these drugs because their use is largely undetectable, as their purchase does not require prescription. To substantiate this hypothesis, further analyses based on large, prospective data collection from the daily clinical practice are needed.
In conclusion, our 'instant picture' of the real medical status of the Ravenna province, as derived from the Pandora database, suggests that it is possible to optimize the therapeutic approach to hypertension and hypercholesterolaemia. This would also mean a significant reduction in the related costs and thus a better allocation of financial resources. Effective, reality-based, continuous medical education is needed, which could also lead to a significant improvement in adherence to the guidelines for the diagnosis and treatment of both hypertension and hypercholesterolaemia and thus to a further improvement in clinical outcomes and the related costs.
